Hims & Hers Health (HIMS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is HIMS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Hims & Hers Health grew its revenue by 49% last quarter. The company incurred a loss, however, as its gross margins deteriorated.…

Revenue is increasing, but so are its operating expenses.…

Commonwealth Equity Services LLC reduced its position in shares of Hims and Hers Health, Inc. (NYSE: HIMS) by 16.1% during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commis…

Hims & Hers stock is facing margin pressure as it increases sales of branded weight-loss drugs and expands internationally. The company has a big opportunity in the peptide market.…

Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.…

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

Even a nearly 9% rebound on Wednesday, Nov. 11, couldn't undo a punishing start to the week for Hims & Hers Health NYSE: HIMS. Shares had already plunged nearly 12% ahead of Monday evening's Q3 earnings report, and disap…

Hims & Hers Health missed Q3 estimates, subscribers fell QoQ, and gross margin declined to a new low. To make matters worse, the company issued weak Q4 and FY2026 guidance. But most of the damage was intentional to set u…

HIMS shares dip nearly 3% after Q3 earnings and revenue miss, a sharp gross margin contraction and lower 2026 adjusted EBITDA guidance.…

I'm downgrading Hims & Hers Health, Inc. to Hold, as Q3 raised more questions than it answered. Revenue grew 49% to $890M, but excluding Eucalyptus, growth was about 26%, and subscribers fell 100K sequentially. Gross mar…

Hims and Hers is bouncing back after a brutal selloff, yet the legal heat keeps rising and its two biggest drug suppliers are sitting out the rally. What does the market see that the lawsuit headlines don't?…

Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.…

Hims & Hers shifts focus on weight-loss expansion and international growth as Q3 margin pressure, subscriber losses and reduced profit guidance cloud its near-term outlook.…

Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly GLP-1 partnership, intern…

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results and trimmed guidance on Monday.…

A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.…

Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and Digital Turbine Inc (…

Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week.…

Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth company's guidance.…

Hims & Hers grew Q3 revenue 49% to $890.4 million, but adjusted EBITDA increased just $4 million to $82.4 million. Gross margin contracted from 73.8% to 57.2%, while subscribers declined 100,000 sequentially despite risi…

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results Monday after the market closed. Also, Needham maintained a Buy rating on…

Hims & Hers cut its 2026 adjusted EBITDA outlook for the third time this year, to $257 million to $277 million from February's $300 million to $375 million, posted a surprise $33 million loss, and CEO Andrew Dudum called…

Revenue grew 49% year-over-year to $890 million in the third quarter. Subscribers reached 2.8 million despite a 100,000 net subscriber decline.…

Hims extends a recent slump after a third-quarter loss, while JBS sinks as Chinese beef import quotas hit the meatpacking business.…

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company's Board of Direct…

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended Septem…

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYS…

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™, and Viome™. The pr…

NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both date…

New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July …

LOS ANGELES, Nov. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) that a securities class action lawsuit has been filed on behalf of shareholders who purchase…

NEW YORK--(BUSINESS WIRE)---- $HIMS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims” or the “Company”) (NYSE: HIMS) an…

LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law.…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

